USA flag logo/image

An Official Website of the United States Government

Exploiting porcine cytomegalovirus stealth mechanisms

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75874
Program Year/Program:
2005 / STTR
Agency Tracking Number:
AI066577
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Xenocept, Inc.
Xenocept, Inc. 1615 Stonehenge Pl Little Rock, AR 72212-0388
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Exploiting porcine cytomegalovirus stealth mechanisms
Agency: HHS
Contract: 1R41AI066577-01
Award Amount: $142,035.00
 

Abstract:

DESCRIPTION (provided by applicant): Pig-to-human xenotransplantation may alleviate the critical shortage of organs available for transplantation. However, hyperacute rejection (HAR), acute vascular rejection (AVR), and cell-mediated rejection pose significant immunological hurdles to making xenotransplantation a clinical reality. Now that pigs lacking a functional alpha-1,3-galactosyltransferase gene have been generated, HAR has been completely eliminated and AVR appears to be substantially reduced. Cell-mediated rejection (i.e., by T cells and NK cells) continues to pose a serious problem. Viruses have evolved a plethora of mechanisms to avoid T cell and NK cell recognition and destruction. The proposed project aims to exploit such "viral stealth" mechanisms for the purpose of xenotransplantation. The focus of the proposed studies will be on porcine cytomegalovirus (PCMV) since it is likely to harbor genes which function optimally in pig cells. Under Specific Aim 1, the complete genome of PCMV will be cloned and sequenced. The goal of Specific Aim 2 is to identify potential immunomodulatory open reading frames (ORFs) of PCMV, first by semi-high throughput assays, and then, for a subset of PCMV ORFs, by more detailed and refined analyses. The Phase I project will be deemed successful when we have identified specific genes from PCMV which impart stealth to pig cells in vitro when exposed to cells from the human immune system.

Principal Investigator:

Mark D. Crew
5016865502
CrewMarkD@uams.edu

Business Contact:


5012287977
Small Business Information at Submission:

Xenocept, Inc.
Xenocept, Inc. 1615 Stonehenge Pl Little Rock, AR 72212

EIN/Tax ID: 200657888
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF ARKANSAS
UNIVERSITY OF ARKANSAS AT LITTLE ROCK
2801 S UNIVERSITY AVE
LITTLE ROCK, AR 72204
RI Type: Nonprofit college or university